Site icon Market Globalist

How Come The Stock Of Aytu Bioscience (AYTU) Is Up 10% Already Before The Market Open?

LPTX Stock

LPTX Stock

The specialty pharmaceutical company Aytu BioScience, Inc. (NASDAQ: AYTU) has been seeing its share price rising 9.84% in the pre-market session today following results of its first-in-human clinical trial for the treatment of COVID-19.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

What does the study reveal?

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Aytu BioScience focuses on the development of novel products to address significant patient needs and bring them to the commercialization stage.  Aytu currently markets a portfolio of prescription pharmaceutical products for the primary and pediatric healthcare markets. A portfolio of the products includes Natesto, ZolpiMist, Tuzistra XR, Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor.

Read More

The company also distributes COVID-19 IgG/IgM rapid antibody tests as well as rapid COVID-19 antigen tests. Diagnostic testing is carried out separately using the two tests to ensure proper diagnostic assessment of the 2019 Novel Coronavirus. Further, Aytu owns the global rights to the Headlight technology platform which the researchers are studying as a prospective treatment for COVID-19 and other respiratory infections.

The first open-label, in-human clinical trial results from the Aytu BioScience in SARS-CoV-2 patients was released on Monday. The pre-print publication was titled:

“Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study”

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Exit mobile version